




Parameswaran Venugopal, MD

The Elodia Kehm Professor and Chair of
Hematology



Advancement of Medicine

In 2023, I progressed with clinical research focusing on my primary area of inquiry: hematologic malignancies. In our lymphoma and myeloma programs, we have been advancing treatment options using several newer modalities of therapies targeting cancer cells in combination with immunotherapeutic agents and small molecules, trying to minimize the use of chemotherapy and radiation therapy and thus reducing short- and long-term adverse events. As you will see from the list of co-authors in the publications listed below, we have achieved national and international recognition in many of these activities.

The insightful research funded by your generosity has not only culminated in noteworthy publications and presentations but has also set a benchmark for hematologists and oncologists across the globe, guiding them towards improved treatment strategies for blood cancers. The extensive list of collaborators highlighted in our publications below is a testament to the far-reaching impact of your support. These national and international partnerships have been instrumental in advancing our collective mission.

Research

Funds from the Elodia Kehm endowment have been utilized for program development in hematology. This includes support of research personnel in the Rush Cancer Clinical Trials Office, faculty and advanced practice providers, or APPs, in the lymphoma program, as well as faculty members in the myelodysplastic/myeloproliferative neoplasms program, the acute leukemia program and the classical hematology program. Your generosity has enabled preparation and submission of



publications to peer review journals as well as membership renewal and conference registration for hematology faculty members.

Grants

The outcomes of research and publications because of the endowment have encouraged support for additional studies and projects in the Section of Hematology.

Publications — Abbreviated

- “A Phase 2 Study of Parsaclisib, a PI3K δ Inhibitor, in Relapsed and Refractory Mantle Cell Lymphoma (CITADEL-205),” *Lancet Oncology* (June 2022) Authors: Pier Luigi Zinzani,¹ Marek Trněný,² Vincent Ribrag,³ Vittorio Ruggiero Zilioli,⁴ Jan Walewski,⁵ Jacob Haaber Christensen,⁶ Vincent Delwail,⁷ Guillermo Rodriguez,⁸ **Parameswaran Venugopal**,⁹ Morton Coleman,¹⁰ Caroline Dartigeas,¹¹ Caterina Patti,¹² Fabrizio Pane,¹³ Wojciech Jurczak,¹⁴ Michal Taszner,¹⁵ Shankara Paneesha,¹⁶ Fred Zheng,¹⁷ Douglas J. DeMarini,¹⁷ Wei Jiang,¹⁷, Aidan Gilmartin,¹⁷ Amitkumar Mehta¹⁸ 11IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, 2Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy; 2Charles University, General Hospital, Prague, Czech Republic; 3Institut Gustave Roussy, Villejuif, France; 4ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; 5Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; 6University of Southern Denmark, Denmark; 7CHU Poitiers, Poitiers, France; 8Hospital Universitario Virgen del Rocío, Seville, Spain; 9Rush University, Chicago, IL, USA; 10New York-Presbyterian/Weill Cornell Medicine, New York, NY; 11CHRU Tours, Tours, France; 12Hematology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy; 13University of Naples Federico II, Naples, Italy; 14Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland; 15Medical University of Gdansk, Gdansk, Poland; 16Birmingham Heartlands Hospital, Birmingham, UK; 17Incyte Corporation, Wilmington, DE, USA; 18UAB School of Medicine, Birmingham, AL, USA
- “Premature ventricular contractions and cardiomyopathy while on ofatumumab for treatment of chronic lymphocytic leukemia,” *European Journal of Case Reports in Internal Medicine*

(2022) Authors: Oladipo Odeyinka, Mitchell Collins, Michael Sunnaa, Parameswaran Venugopal, Tochukwu Okwuosa, Rush University Medical Center, Chicago.

- “Prospective multicenter phase I/II trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated diffuse large B-cell lymphoma,” submitted to *Blood Advances* (2023) Authors: Kirk Cahill MD1, James Godfrey MD2, Chadi Nabhan MD MBA3, Justin Kline MD1, Peter Riedell MD1, Kenneth S. Cohen MD1, Sunil Narula MD1, Theodore G. Karrison PhD4, Jessica Robertson CCRP1, Reem Karmali MD MS5, Parameswaran Venugopal MD6, Seo-Hyun Kim MD6, Aaron P. Rapoport MD7, Seung Tae Lee MD7, Jennie Law MD7, Paul Fishkin MD8, Iris Isufi MD9, James Wade MD10, Lynne Kaminer MD11, Sonali M. Smith MD.
- “Acalabrutinib alone or in combination with rituximab for follicular lymphoma: an open-label study,” submitted to *BLOOD* (2024). Authors: Paolo Strati ,1 Rebecca Champion,2 Morton Coleman,3 Sonali M. Smith,4 Parameswaran Venugopal,5 Peter Martin,6 Andrew Wood,7 Kara Miller,8 Beth Christian91The University of Texas MD Anderson Cancer Center, Houston, TX, USA ; 2Norton Cancer Institute, Louisville, KY, USA; 3Clinical Research Alliance/Weill Cornell Medicine, New York, NY, USA; 4The University of Chicago Medical Center, Chicago, IL, USA; 5Rush University Medical Center, Chicago, IL, USA; 6Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; 7AstraZeneca, Cambridge, UK; 8AstraZeneca, South San Francisco, CA, USA; 9The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Presentations

- American Society of Hematology Annual Meeting, December 2022: “Acalabrutinib Plus Rituximab with or Without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial,” poster presentation; “Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas.” Abstract #2936.
- American College of Cardiology/World Congress of Cardiology Annual Meeting in New Orleans, March 2023: “Premature Ventricular Contractions and Cardiomyopathy while on Ofatumumab for Treatment of Chronic Lymphocytic Leukemia.”



- 65th ASH Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California: “A Phase Ib Study to Evaluate the Safety and Efficacy of Nivolumab in Combination with R-CHOP in High-Risk DLBCL.” Poster presentation session.
- ARRS conference (American Roentgen Ray Society) at Boston, MA in May 2024: “AI generated Δ (delta) SUVmax and Δ Mean Tumor Volume (Δ MTV) improves confidence in clinical decision making on Interim and/or completion 18F-FDG PET/CT in lymphoma patients with Deauville Score of 4.” Presentation.
- International Myeloma Society meeting at Athens, Greece, April 2023: “Soluble Urokinase Plasminogen Activator Receptor (SuPAR) in patients with plasma cell dyscrasias, a pilot study.” Presentation.

The Year Ahead: 2024 and Beyond

We plan to enhance research focused on improving immunotherapy and cellular therapy options for patients with hematologic malignancies using the funds provided by your endowment. We will continue to have regular interactions with the community of oncologists, including educational programs.

With Gratitude

We extend our deepest gratitude for your invaluable support of our program development and the pioneering clinical and translational research within the Section of Hematology. Your generous contribution has significantly bolstered our faculty and research teams, empowering them to enhance patient care for those suffering from both benign and malignant hematological conditions. Your philanthropy has truly set the stage for transformative discoveries and patient care advancements, echoing your commitment to bettering lives.